SANTA CLARA, Calif.--(BUSINESS WIRE)--Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure, today announced its activities at the upcoming, first ever Technology and Heart Failure Therapeutics conference (THT 2022), which is produced by the Cardiovascular Research Foundation (CRF) and will be held February 1-2 at the New York Marriott Marquis.
Ancora Heart is spotlighting the updated, complete 12-month clinical outcomes from an analysis of early feasibility, safety and performance studies evaluating the investigational AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure with reduced ejection fraction (HFrEF). Events at THT 2022 where Ancora Heart and the AccuCinch System will be highlighted include:
Sponsored Satellite Symposium: Transcatheter Left Ventricular Restoration in the Pharmacologically Optimized HFrEF Patient with Persistent Symptoms: An Investigational Option to Alter Disease Course?
- Tuesday, February 1, 2022 from 6:00 – 7:30 p.m.; Julliard Complex, 5th Floor
Transcatheter Ventricular Remodeling for Heart Failure
- Wednesday, February 2, 2022: 3:15-4:10 p.m.; Westside Ballroom, 5th floor
Covering a full range of updates on the status of drug- and device-based treatments for heart failure that have not yet appeared in treatment guidelines, THT 2022 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.
About the AccuCinch Ventricular Restoration System
The AccuCinch System is designed to augment the existing care cardiologists provide their heart failure (HF) patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant.
During the minimally invasive AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. The AccuCinch System may help reduce symptoms, improve quality of life and potentially increase life expectancy.
The CORCINCH-HF pivotal trial is underway, designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This study is being conducted to support the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA).
About Ancora Heart
Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch® Ventricular Restoration System is the only completely transcatheter device designed to restore the structure and function of the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of heart failure in patients with reduced ejection fraction (HFrEF). The AccuCinch System is an investigational device, which is currently being studied in the CORCINCH-HF pivotal trial, a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation (ClinicalTrials.gov Identifier: NCT04331769). Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, please visit www.ancoraheart.com and connect on Twitter (@AncoraHeart), LinkedIn and Facebook.